Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:1540 |
| Name | parathyroid carcinoma |
| Definition | An endocrine gland cancer located_in the parathyroid glands located in the neck. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:11006 DOID:1541 |
| Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer parathyroid carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT04106843 | Phase II | Lutetium Lu 177 dotatate | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | Withdrawn | USA | 0 |
| NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Active, not recruiting | BRA | 0 |
| NCT07163325 | Phase I | EP102 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | Recruiting | NLD | ESP | CZE | BEL | 0 |